Abbott’s Branded Drug Spin-off Will Boost Profile Of Diversified Device Biz
This article was originally published in The Gray Sheet
Abbott’s planned spin-off of its branded pharmaceuticals business will raise the profile of its remaining diversified device and diagnostics business while isolating certain long-term risks, including generic drug competition.
You may also be interested in...
Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.
Kidney dialysis and biosurgery will be two major focus points for a newly refined Baxter after it spins off its biopharmaceuticals business, as planned for mid-2015.
House Majority leader floats device tax repeal as fiscal cliff issue. The U.S. Preventative Services Task Force issued draft recommendations with middling support for hepatitis C screening in the general baby-boomer population. More news.